Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 132
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring
Christeen Samuel, Hannah Cornman, Anusha Kambala, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 3, pp. 729-749
Open Access | Times Cited: 107
Comorbidities of atopic dermatitis—what does the evidence say?
Jacob P. Thyssen, Anne‐Sofie Halling, Peter Schmid‐Grendelmeier, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 151, Iss. 5, pp. 1155-1162
Open Access | Times Cited: 68
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 18
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Huibin Yang, Ting An, Yuxuan Zhao, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 3
The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials
Sanghyuk Yoon, Kihun Kim, Kihyuk Shin, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1, pp. 52-61
Closed Access | Times Cited: 32
Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases
Jenne P. Ingrassia, Muhammad Haisum Maqsood, Joel M. Gelfand, et al.
JAMA Dermatology (2023) Vol. 160, Iss. 1, pp. 28-28
Closed Access | Times Cited: 30
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
Helena Iznardo, Esther Roé, E. Serra‐Baldrich, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 385-385
Open Access | Times Cited: 21
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors
Mircea Tampa, Cristina Iulia Mitran, Mădălina Irina Mitran, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 384-384
Open Access | Times Cited: 19
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Eduardo Mysler, Gerd R Burmester, Christopher D. Saffore, et al.
Advances in Therapy (2024) Vol. 41, Iss. 2, pp. 567-597
Open Access | Times Cited: 7
Multimorbidity disease clusters are associated with venous thromboembolism: an extended cross-sectional national study
Jonatan Ahrén, Mirnabi Pirouzifard, Björn Holmquist, et al.
Journal of Thrombosis and Thrombolysis (2024) Vol. 57, Iss. 6, pp. 898-906
Open Access | Times Cited: 6
Comparative safety of oral Janus kinase inhibitors and dupilumab in patients with atopic dermatitis: a population-based cohort study
Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 154, Iss. 5, pp. 1195-1203.e3
Closed Access | Times Cited: 6
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
J Zhang, Wenhui Li, Mingli Gong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Risk Factors that Impact Treatment with Oral Janus Kinase Inhibitors Among Adult Patients with Atopic Dermatitis: A Nationwide Registry Study
Ida Vittrup, David Thein, Simon Francis Thomsen, et al.
Acta Dermato Venereologica (2024) Vol. 104, pp. adv18638-adv18638
Open Access | Times Cited: 5
Venous thromboembolism in bullous pemphigoid: current evidence and update on systematic review
Atheer G. Almutairi, Abeer T. Almutairi, Rahaf Almutairi, et al.
Dermatology Reports (2025)
Open Access
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter Study
Francesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Risk Assessment in Atopic Dermatitis: Guidance from a Multidisciplinary Expert Panel
Alessandra Narcisi, Vito Di Lernia, Maria Esposito, et al.
Dermatology and Therapy (2025)
Open Access
Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis
Tai‐Li Chen, Wan‐Ting Huang, Ching‐Hui Loh, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 7, pp. 720-720
Open Access | Times Cited: 9
Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis
Chen Sun, Zheng Su, Yueping Zeng
Inflammation Research (2023) Vol. 72, Iss. 9, pp. 1861-1871
Closed Access | Times Cited: 9
Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
Qingying He, Xin Xie, Qian Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Comparison of Old and New Systemic Treatments for Moderate to Severe Atopic Dermatitis
Hyun Jin Yim, Tiffany Jean, Peck Y. Ong
Current Allergy and Asthma Reports (2024) Vol. 24, Iss. 5, pp. 289-301
Open Access | Times Cited: 3
Non‐biologic systemic treatments for atopic dermatitis: Current state of the art and future directions
Alexandra Paolino, H Alexander, Conor Broderick, et al.
Clinical & Experimental Allergy (2023) Vol. 53, Iss. 5, pp. 495-510
Open Access | Times Cited: 8
Long-Term Safety Profile and Off-Label Use of JAK Inhibitors in Dermatological Disorders
L. Corbella‐Bagot, Constanza Riquelme‐Mc Loughlin, D. Morgado-Carrasco
Actas Dermo-Sifiliográficas (2023) Vol. 114, Iss. 9, pp. 784-801
Open Access | Times Cited: 8
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Yekaterina Tokareva, Pankti Reid, Victor Yang, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 11, pp. 1385-1397
Open Access | Times Cited: 8
Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data
Joseph F. Merola, Brennan Ertmer, Huifang Liang, et al.
Journal of the American Academy of Dermatology (2023) Vol. 90, Iss. 5, pp. 935-944
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top